CCL2 and lung cancer: In lung cancer models, the chemokine monocyte chemoattractant protein-1 (CCL2) positively correlates with MDSC frequency, and antibody-mediated blockade of CCL2 reduces both G-MDSCs and M-MDSCs in tumours reducing iNOS and Arg1 expression [75].